免疫性血小板缺血的治疗:从历史的角度来看的背景
Daniel Martínez-Carballeira1,2, Ángel Bernardo1,2, Alberto Caro1,2
1Department of Hematology, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.
Hematology reports
|July 25, 2024
概括
免疫性血小板缺血 (ITP) 是一种自身免疫性出血疾病. 本综述涵盖ITP治疗,从初始疗法到管理困难病例.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 免疫性血小板缺血 (ITP) 是一种自身免疫性疾病.
- 具有低血小板数和出血风险的特征.
- 复杂的致病性涉及免疫系统功能障碍影响血小板的生产和破坏.
研究的目的:
- 为提供免疫性血小板缺血 (ITP) 治疗的历史概述.
- 讨论当前的一线和二线治疗策略.
- 概述管理耐火ITP病例的方法.
主要方法:
- 关于免疫性血小板缺血 (ITP) 治疗的文献综述.
- 治疗进化的历史分析.
- 讨论当前的临床指导方针和管理方案.
主要成果:
- 第一线治疗通常涉及皮质类固醇或静脉注射免疫球蛋白.
- 第二线的选择包括Rituximab,血栓形成素受体激动剂和脊髓切除术.
- 耐火性ITP的管理需要个性化的方法,可能包括新的治疗方法.
结论:
- 治疗ITP已经显著发展,提供了多样化的选择.
- 有效的管理需要了解疾病的发病因子和患者特异性因素.
- 持续的研究对于改善耐火性免疫性血小板缺血 (ITP) 的结果至关重要.
相关概念视频
Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
663
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
663
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Tumor Immunotherapy
501
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
501


